Axitinib Therapy Management Study
NCT04555603 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2023-11-21
Summary
The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI
Conditions
Interventions
- DRUG
-
Inlyta
axitinib
- DRUG
-
Bavencio
avelumab
- DRUG
-
Pembrolizumab
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-15
- Primary Completion
- 2021-02-22
- Completion
- 2021-02-22
Countries
- United States
Study Locations
More Related Trials
-
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
NCT00835978 ·Status: COMPLETED ·Phase: PHASE2
-
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
NCT05096390 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
NCT04522323 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
NCT02493751 ·Status: COMPLETED ·Phase: PHASE1
-
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
NCT02579811 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
NCT05733715 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
NCT01599754 ·Status: TERMINATED ·Phase: PHASE3
-
Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
NCT02002312 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
NCT00282048 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
NCT07011849 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
NCT04267120 ·Status: TERMINATED ·Phase: PHASE2
-
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
NCT04995016 ·Status: UNKNOWN ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
NCT02853331 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
NCT01255137 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02684006 ·Status: COMPLETED ·Phase: PHASE3
-
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
NCT01056263 ·Status: COMPLETED
-
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
NCT05663710 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
NCT04941768 ·Status: COMPLETED
-
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT03297593 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
NCT00569946 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy in Treating Patients With Advanced Kidney Cancer
NCT00011973 ·Status: COMPLETED ·Phase: PHASE2
-
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
NCT06279403 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT03172754 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
NCT03595124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2